drugset / Trial / NCT06032000
Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A dose-escalation, double-blinded, randomized, placebo-controlled phase 1 study to assess the safety, reactogenicity, and immunogenicity of a SARS-CoV-2 Booster Vaccine (LEM-mR203) in healthy adults aged at 19 to 55 years
Timeline
- Start
- 2023-11-06
- Primary completion
- 2025-03-28
- Completion
- 2025-03-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | LEM-mR203 | Messenger RNA (mRNA) | — | Intramuscular |